DV
Dividend Vision

NAMS — NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. (NAMS)

Total return is 149.8% over the past 5.5 years, 35.7 points ahead of SPY at 114.1%. Its deepest 1-year drawdown was 35.7%.

NAMS is a healthcare equity stock that trades on public markets. As a single-stock holding rather than a diversified fund, it does not have a distribution rate, expense ratio, or fund-level characteristics typical of ETFs. This security appeals primarily to investors seeking direct exposure to a specific pharmaceutical company rather than those pursuing broad dividend income strategies.

NAMS key facts

Asset type
Stock
Asset class
Equity
Inception date
02/08/2021
Distribution frequency
None
Last close
$26.98
Market cap
$3,154,069,248
Average volume
959700.0
Beta
0.11
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.16